GlassScriptPhysician profile
Vincent D Mallory
NPI 1215918503
$10,363.10
in general payments reported to CMS, 2019-2025
42 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,112 · 2020: $1,559 · 2021: $2,221 · 2022: $1,488 · 2023: $609 · 2024: $121 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,571.57 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $1,475.67 | 2019-2024 | Wegovy |
| Amgen INC. | $1,131.09 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $756.90 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $742.14 | 2019-2022 | |
| Allergan, INC. | $511.75 | 2019-2020 | |
| Lilly USA, LLC | $469.16 | 2019-2025 | Mounjaro |
| Abbvie INC. | $386.76 | 2021-2023 | |
| Pfizer INC. | $335.45 | 2019-2021 | |
| Genzyme Corporation | $318.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $284.13 | 2019-2023 | Arexvy |
| Amarin Pharma, INC. | $219.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $180.77 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $151.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.25 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Mallory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.